MYCN and medulloblastoma: Notably, the combination of CD532, which disrupts the interaction between AURK and MYCN, and verteporfin, a YAP inhibitor, was associated with a dramatic suppression of tumor growth both in vitro and in vivo and an increased survival of SHH-activated medulloblastoma-bearing mice [100].